Pregene Biopharma Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Pregene Biopharma Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Pregene Biopharma presents a practical BD-screening case because its returned pipeline contains 17 records and the deal search returned 6 transaction records. The lead returned asset is Ribrecabtagene autoleucel, associated with BCMA and Multiple Myeloma, Purpura, Thrombocytopenic, Idiopathic, Immunoglobulin G4-Related Disease, at Phase 2. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Ribrecabtagene autoleucel | Shenzhen Puruijin Biological Pharmaceutical Co., Ltd. | Phase 2 | Pipeline record: BCMA; Multiple Myeloma, Purpura, Thrombocytopenic, Idiopathic, Immunoglobulin G4-Related Disease. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Pregene and Kite Entered into Strategic Collaboration | Phase 2 asset with BCMA exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | PRG-2302 | Shenzhen Puruijin Biological Pharmaceutical Co., Ltd. | Phase 1 | Pipeline record: target not returned; CD19-positive B-cell acute lymphoblastic leukemia, Recurrent B Acute Lymphoblastic Leukemia. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 普瑞金与Galapagos （Gilead伙伴公司）就中国和印度以外市场达成授权合作 | Phase 1 asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | CD19/BCMA CAR-T (Shenzhen Puruijin Biological Pharma) | Shenzhen Puruijin Biological Pharmaceutical Co., Ltd. | Phase 1 | Pipeline record: BCMA x CD19; Immunoglobulin G4-Related Disease, Lupus Nephritis, Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 普瑞金生物与CellPoint B.V.达成欧美授权 | Phase 1 asset with BCMA x CD19 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | ESO-T01(EsoBiotec) | Shenzhen Puruijin Biological Pharmaceutical Co., Ltd. | Phase 1 | Pipeline record: BCMA; Refractory Multiple Myeloma, Relapse multiple myeloma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Pregene and Kite Entered into Strategic Collaboration | Phase 1 asset with BCMA exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | Tcr-T Cells Targeting HLA-A*02:01/NY-ESO-1(Shenzhen Puruijin Biological Pharmaceutical) | Shenzhen Puruijin Biological Pharmaceutical Co., Ltd. | IND Approval | Pipeline record: HLA-A2 x NY-ESO-1; Sarcoma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 普瑞金与Galapagos （Gilead伙伴公司）就中国和印度以外市场达成授权合作 | IND Approval asset with HLA-A2 x NY-ESO-1 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2025-10-16 | Pregene and Kite Entered into Strategic Collaboration | Active | disclosed: false |
| 2022-09-27 | 普瑞金与Galapagos （Gilead伙伴公司）就中国和印度以外市场达成授权合作 | Active | total_amount: 272.85; disclosed: false |
| 2022-04-02 | 普瑞金生物与CellPoint B.V.达成欧美授权 | Active | upfront_payment: 22.1039; disclosed: true |
The most relevant returned precedent is: Pregene and Kite Entered into Strategic Collaboration (2025-10-16). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- PEREGRINE PHARMACEUTICALS INC - Prospectus(U.S. Stocks): PEREGRINE PHARMACEUTICALS INC - Prospectus(U.S. Stocks) [PEREGRINE LOGO] Given the uncertainty of the availability of cash from the capital markets and the potential restrictions and limitations we have for equity or debt financings, the Company is actively exploring various other sources of cash by leveraging its many assets. The transactions being explored by the Company for its technologies include licensing or partnering Cotara(TM), licensing, partnering or divesting Oncolym(R), divesting all radiopharmaceutical based technologies (Oncolym(R), Cotara(TM) (TNT based therapeutic and imaging uses)) and VTA based radiopharmaceuticals for therapeutic and imaging uses, licensing or partnering the Company's lead VEA clinical candidate, NHS76/PEP and licensing or partnering our various VTA bas
- Provention Bio, Inc. - 2022 Quarterly report: Provention Bio, Inc. - 2022 Quarterly report 2. LIQUIDITY The timing and outcome of the Company’s regulatory activities for teplizumab will impact the Company’s cash runway. If the Company’s teplizumab BLA resubmission is approved by the FDA and the Company does not otherwise raise additional capital, the Company will encounter near-term liquidity needs. Factors that could impact the Company’s cash runway include, but are not limited to, the Company’s plans for and potential changes to estimated costs of commercialization and potential milestone payments that may be triggered under the Company’s current agreements, including with MacroGenics. The Company will require substantial additional financing to fund its operations, to continue to execute its strategy, and to continue as a going con
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Pregene Biopharma is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Pregene Biopharma merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Ribrecabtagene autoleucel, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
